Članki z zahtevami za javni dostop - alastair greystokeVeč o tem
Ni na voljo nikjer: 5
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial
DA Fennell, A King, S Mohammed, A Greystoke, S Anthony, C Poile, ...
The Lancet Oncology 23 (3), 374-381, 2022
Zahteve: Cancer Research UK
The effect of food or omeprazole on the pharmacokinetics of osimertinib in patients with non‐small‐cell lung cancer and in healthy volunteers
K Vishwanathan, PA Dickinson, K Bui, PA Cassier, A Greystoke, E Lisbon, ...
The Journal of Clinical Pharmacology 58 (4), 474-484, 2018
Zahteve: Cancer Research UK
A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors
B Milojkovic Kerklaan, S Slater, M Flynn, A Greystoke, PO Witteveen, ...
Investigational new drugs 34, 329-337, 2016
Zahteve: Cancer Research UK, National Institute for Health Research, UK
Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer
R Califano, A Greystoke, R Lal, J Thompson, S Popat
Lung Cancer 111, 51-58, 2017
Zahteve: National Institute for Health Research, UK
Nonadditive Effects of Common Genetic Variants Have a Negligent Contribution to Cancer Heritability
A Hammermeister Suger, TA Harrison, B Henning, C Turman, P Kraft, ...
Cancer Epidemiology, Biomarkers & Prevention 33 (10), 1383-1388, 2024
Zahteve: National Health and Medical Research Council, Australia, Fonds de recherche …
Na voljo nekje: 54
Evaluation and prognostic significance of circulating tumor cells in patients with non–small-cell lung cancer
MG Krebs, R Sloane, L Priest, L Lancashire, JM Hou, A Greystoke, ...
Journal of clinical oncology 29 (12), 1556-1563, 2011
Zahteve: Cancer Research UK
Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer
JM Hou, MG Krebs, L Lancashire, R Sloane, A Backen, RK Swain, ...
Journal of Clinical Oncology 30 (5), 525-532, 2012
Zahteve: Cancer Research UK
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer
CL Hodgkinson, CJ Morrow, Y Li, RL Metcalf, DG Rothwell, F Trapani, ...
Nature medicine 20 (8), 897-903, 2014
Zahteve: Cancer Research UK
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy
JM Hou, A Greystoke, L Lancashire, J Cummings, T Ward, R Board, ...
The American journal of pathology 175 (2), 808-816, 2009
Zahteve: Cancer Research UK
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer
RE Board, AM Wardley, JM Dixon, AC Armstrong, S Howell, L Renshaw, ...
Breast cancer research and treatment 120, 461-467, 2010
Zahteve: Cancer Research UK
The National Lung Matrix Trial of personalized therapy in lung cancer
G Middleton, P Fletcher, S Popat, J Savage, Y Summers, A Greystoke, ...
Nature 583 (7818), 807-812, 2020
Zahteve: Cancer Research UK, UK Medical Research Council, Wellcome Trust
First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014
B Basu, E Dean, M Puglisi, A Greystoke, M Ong, W Burke, M Cavallin, ...
Clinical cancer research 21 (15), 3412-3419, 2015
Zahteve: Cancer Research UK, National Institute for Health Research, UK
Optimisation of circulating biomarkers of cell death for routine clinical use
A Greystoke, J Cummings, T Ward, K Simpson, A Renehan, F Butt, ...
Annals of oncology 19 (5), 990-995, 2008
Zahteve: Cancer Research UK
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours
G Mak, JC Soria, SP Blagden, R Plummer, RA Fleming, N Nebot, J Zhang, ...
British journal of cancer 120 (10), 975-981, 2019
Zahteve: Cancer Research UK, National Institute for Health Research, UK
A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer
S Halford, GJ Veal, SR Wedge, GS Payne, CM Bacon, P Sloan, I Dragoni, ...
Clinical Cancer Research 29 (8), 1429-1439, 2023
Zahteve: US National Institutes of Health, Cancer Research UK, UK Engineering and …
Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma
A Greystoke, JPB O'Connor, K Linton, MB Taylor, J Cummings, T Ward, ...
British journal of cancer 104 (4), 719-725, 2011
Zahteve: Cancer Research UK
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial
HL Kindler, S Novello, A Bearz, GL Ceresoli, JGJV Aerts, J Spicer, ...
The Lancet Oncology 23 (4), 540-552, 2022
Zahteve: US National Institutes of Health
Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer
A Greystoke, E Dean, MP Saunders, J Cummings, A Hughes, M Ranson, ...
British journal of cancer 107 (9), 1518-1524, 2012
Zahteve: Cancer Research UK
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study
PA Zucali, CC Lin, BC Carthon, TM Bauer, M Tucci, A Italiano, R Iacovelli, ...
Journal for immunotherapy of cancer 10 (1), e003697, 2022
Zahteve: National Institute for Health Research, UK
CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer
GM Walls, JB Oughton, AJ Chalmers, S Brown, F Collinson, MD Forster, ...
Clinical and translational radiation oncology 25, 61-66, 2020
Zahteve: Cancer Research UK, UK Medical Research Council, National Institute for …
Podatke o objavi in financiranju samodejno določi računalniški program